Metallo-drugs in cancer therapy: Past, present and future
Cancer treatments which include conventional chemotherapy have not proven very
successful in curing human malignancies. The failures of these treatment modalities include …
successful in curing human malignancies. The failures of these treatment modalities include …
NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
Thirty years of the drug candidate NAMI‐A and the myths in the field of ruthenium anticancer compounds: a personal perspective
E Alessio - European Journal of Inorganic Chemistry, 2017 - Wiley Online Library
As anticipated in the title, this contribution is basically divided into two, strictly connected,
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …
parts. The first is a personal overview of the ruthenium drug candidate NAMI‐A, almost 30 …
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
R Trondl, P Heffeter, CR Kowol, MA Jakupec… - Chemical …, 2014 - pubs.rsc.org
NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development
against solid cancer and has recently been studied successfully in a phase I clinical trial …
against solid cancer and has recently been studied successfully in a phase I clinical trial …
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
S Leijen, SA Burgers, P Baas, D Pluim, M Tibben… - Investigational new …, 2015 - Springer
Summary Background This phase I/II study determined the maximal tolerable dose, dose
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
JM Rademaker-Lakhai, D Van Den Bongard… - Clinical Cancer …, 2004 - AACR
Abstract Purpose: NAMI-A {H2Im [trans-RuCl4 (DMSO) HIm] or imidazolium-trans-DMSO-
imidazole-tetrachlororuthenate} is a novel ruthenium-containing compound that has …
imidazole-tetrachlororuthenate} is a novel ruthenium-containing compound that has …
Ruthenium-based chemotherapeutics: are they ready for prime time?
ES Antonarakis, A Emadi - Cancer chemotherapy and pharmacology, 2010 - Springer
Since the discovery of cis-platinum, many transition metal complexes have been
synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based …
synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based …
In vitro and in vivo evaluation of ruthenium (II)− arene PTA complexes
C Scolaro, A Bergamo, L Brescacin… - Journal of medicinal …, 2005 - ACS Publications
The antitumor activity of the organometallic ruthenium (II)− arene complexes, RuCl2 (η6-
arene)(PTA),(arene= p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2, 3 …
arene)(PTA),(arene= p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2, 3 …
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …
Recent developments in ruthenium anticancer drugs
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH+)[RuIIICl4
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …